PPTA Press Releases
International Plasma Awareness Week 2022: Donate Locally. Think Globally.
ANNAPOLIS, MD (October 3, 2022) — The Plasma Protein Therapeutics Association (PPTA) is proud to mark the launch of the 10th annual International Plasma Awareness Week (IPAW), which will run from Monday, October 3 until Friday, October 7. Hundreds of thousands of people in the U.S. who live with these rare diseases, and countless others facing trauma and emergency medical needs every day, rely on plasma-derived therapies that are only available because of the commitment of dedicated plasma donors.
PPTA Statement on the draft EU Substances of Human Origin Regulation
Brussels, Belgium (July 14, 2022). While the text of the draft regulation on Substances of Human Origin (SoHo) addresses a number of PPTA’s concerns, it has missed the opportunity to help Member States increase plasma collection to improve the reliable availability of life-saving, plasma-derived therapies to patients with a wide range of rare and complex, chronic diseases. As much as 38% of the plasma used to produce medicines for the EU’s 300,000 rare disease patients who rely on PDMPs comes from the U.S., a reliance highlighted during the pandemic, when critical plasma donations declined significantly.
A missed opportunity to acknowledge EU’s dependency on U.S. plasma
Brussels, Belgium (December 17) The Plasma Protein Therapeutics Association (PPTA) regrets that the publication of the European Commission report, “Study on medicine shortages,” does not include plasma, which is a biological starting material for the manufacture of lifesaving plasma-derived medicinal products (PDMPs). PDMP availability is primarily dependent on volumes of plasma collected, which are currently insufficient to meet the needs of EU patients.
Adoption of the EP report “EU Pharmaceutical Strategy”
Brussels, Belgium (November 24) — The Plasma Protein Therapeutics Association (PPTA) congratulates MEP Montserrat (EPP, Spain) for the adoption of the report “EU Pharmaceutical Strategy” during the European Parliament’s Plenary session. The report was adopted by 527 MEPs on Wednesday 24 November.
International Plasma Awareness Week 2021: Donate Plasma. Save Lives.
ANNAPOLIS, MD (October 4, 2021) — The Plasma Protein Therapeutics Association (PPTA) is proud to mark the launch of the ninth annual International Plasma Awareness Week (IPAW), which will run from Monday, October 4 until Friday, October 8. Nearly 125,000 people in the U.S. with rare diseases, and countless others facing trauma and emergency medical needs every day, rely on medicines that are only available because of the commitment of dedicated plasma donors. Considering the nearly 20% decline in plasma donations seen last year due to the ongoing pandemic, the need for plasma donors is now more urgent than ever before.
Calling on EU Policymakers to Increase Plasma Donations
Brussels, (October 4, 2021) — The Plasma Protein Therapeutics Association (PPTA) is marking the 9th annual International Plasma Awareness Week (IPAW), October 4-8, by increasing awareness and understanding about the importance of plasma, particularly the urgent need to increase plasma donations in the European Union, while also recognizing and thanking plasma donors who save and improve the lives of patients who rely on plasma for their therapies. Considering the revision of the European blood and tissues and cells legislation, PPTA calls on policymakers and regulators throughout Europe to strengthen its legal framework to benefit plasma donations for plasma-derived medicines and encourage new approaches that increase the collection of plasma across the European Union.
PPTA Executive Summary of FDA’s U.S. Immunoglobulin Utilization Study Report
The CBER Surveillance Program BEST Initiative recently posted its Assessment of Immune Globulin Utilization in Commercially insured and Medicare Populations study report. The aim of the study is to provide a better picture of the evolution of Ig use over a 10-year longitudinal period in the context of emerging scientific evidence and clinical trends. PPTA developed an Executive Summary of the study report, highlighting key observations, findings, and conclusions.
Monkeypox Virus and Plasma Protein Therapies
PPTA considers that the current MPXV outbreak is not a concern for the safety margins of plasma protein therapies manufactured by PPTA member companies. This assessment is also shared by other concerned parties (AABB, WHO). Since May 2022, Monkeypox virus (MPXV) infections have been reported in non-endemic countries across Europe and North America (WHO, CDC, ECDC). People who use plasma protein therapies are understandably concerned about whether their therapies remain safe, with respect to MPXV. To address this issue, PPTA has summarized currently available facts.
Announcing PPTA’s New Global Chair
It is with great pleasure that the Plasma Protein Therapeutics Association (PPTA) announces the election of Giles Platford from Takeda to the Chair of the PPTA Global Board. Giles takes the helm of PPTA at a time of heightened awareness of plasma donation, with significant opportunity to broaden understanding of the plasma protein therapeutics sector. Together with other members of the Global Board, Giles will support PPTA’s goals to improve understanding of the need for plasma, highlighting the importance, unique nature and value of plasma therapies to rare disease communities globally.
PPTA Statement on the Ukraine Crisis
The Plasma Protein Therapeutics Association (PPTA) expresses serious concern about the ongoing hostilities in Ukraine and the devastating impact on the lives of people in the region. As an association representing plasma collectors and manufacturers dedicated to saving and improving human lives, our primary focus remains on ensuring that patients have access to the essential plasma-derived treatments they rely on. Our member companies are making every effort to secure access for patients in the affected region during the conflict and in its aftermath.
The Source Magazine (2021-2016)
The Plasma Pool